Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies

Mehdi Hamadani,Laura Liao, Tony Yang,Lei Chen,Craig Moskowitz

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 1|浏览4

暂无评分

摘要

In this study, a majority of r/r DLBCL patients were treated with CT/CIT or TT in 3L and 4L settings and had poor clinical outcomes, underscoring the need for more effective treatments.

查看译文

关键词

Overall survival,Response rates,Chemotherapy or chemoimmunotherapy (CT/CIT),Targeted therapy (TT),Chimeric antigen receptor T cells (CAR-T)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要